344.5K XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Timothy A. Springer | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 50.00 per share. | 05 Feb 2025 | 660,000 | 970,223 | - | 50 | 33,000,000 | Common Stock |
| Timothy A. Springer | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 54.14 per share. | 05 Feb 2025 | 129,294 | 4,226,058 | - | 54.1 | 6,999,977 | Common Stock |
| Daniel Lochner | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 54.14 per share. | 05 Feb 2025 | 4,617 | 4,617 | - | 54.1 | 249,964 | Common Stock |
| Alise S. Reicin | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 101,953 | 101,953 | - | - | Employee Stock Option (Right to Buy) | |
| Alise S. Reicin | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 36,047 | 214,344 | - | 0 | Common Stock | |
| Daniel Lochner | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 18,074 | 18,074 | - | 0 | Common Stock | |
| Daniel Lochner | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 32,862 | 32,862 | - | - | Employee Stock Option (Right to Buy) | |
| Marcella Kuhlman Ruddy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 32,502 | 32,502 | - | - | Employee Stock Option (Right to Buy) | |
| Marcella Kuhlman Ruddy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 17,876 | 49,941 | - | 0 | Common Stock | |
| Peter McNamara | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 15,141 | 29,329 | - | 0 | Common Stock | |
| Peter McNamara | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 27,530 | 27,530 | - | - | Employee Stock Option (Right to Buy) | |
| Marc Schwabish | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 14,023 | 18,723 | - | 0 | Common Stock | |
| Marc Schwabish | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 25,496 | 25,496 | - | - | Employee Stock Option (Right to Buy) | |
| Marc Schwabish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.38 per share. | 28 Jan 2025 | 2,700 | 4,700 | - | 2.4 | 6,426 | Common Stock |
| Marc Schwabish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2025 | 2,700 | 86,514 | - | - | Employee Stock Option (Right to Buy) | |
| Marc Schwabish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 2,000 | 89,214 | - | - | Employee Stock Option (Right to Buy) | |
| Marc Schwabish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.38 per share. | 09 Dec 2024 | 2,000 | 2,000 | - | 2.4 | 4,760 | Common Stock |
| Alise S. Reicin | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2024 | 11,717 | 178,297 | - | 0 | Common Stock | |
| Alise S. Reicin | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2024 | 6,000 | 6,000 | - | - | Employee Stock Option (Right to Buy) | |
| Peter McNamara | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 3,500 | 34,459 | - | - | Employee Stock Option (Right to Buy) | |
| Peter McNamara | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.38 per share. | 03 Dec 2024 | 3,500 | 14,188 | - | 2.4 | 8,330 | Common Stock |
| Timothy A. Springer | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 33.59 per share. | 22 Oct 2024 | 300,000 | 4,096,764 | - | 33.6 | 10,077,000 | Common Stock |
| Timothy A. Springer | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 24 Sep 2024 | 1,240,893 | 310,223 | - | 0 | Common Stock | |
| Timothy A. Springer | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 30.87 per share. | 24 Sep 2024 | 2,400 | 3,796,764 | - | 30.9 | 74,088 | Common Stock |
| Timothy A. Springer | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 30.10 per share. | 24 Sep 2024 | 4,070 | 3,794,364 | - | 30.1 | 122,507 | Common Stock |
| Timothy A. Springer | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 29.13 per share. | 24 Sep 2024 | 18,999 | 3,790,294 | - | 29.1 | 553,441 | Common Stock |
| Timothy A. Springer | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 28.16 per share. | 24 Sep 2024 | 24,531 | 3,771,295 | - | 28.2 | 690,793 | Common Stock |
| Timothy A. Springer | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 24 Sep 2024 | 186,134 | 186,134 | - | 0 | Common Stock | |
| Timothy A. Springer | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 24 Sep 2024 | 1,054,759 | 3,746,764 | - | 0 | Common Stock | |
| Phillip B. Donenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,760 | 11,760 | - | - | Stock Option (Right to Buy) | |
| Timothy A. Springer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,692,005 | 2,692,005 | - | - | Common Stock | |
| Timothy A. Springer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,760 | 11,760 | - | - | Stock Option (Right to Buy) | |
| Timothy A. Springer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 1,551,116 | 1,551,116 | - | - | Common Stock | |
| Christian Cortis | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 56,061 | 56,061 | - | - | Employee Stock Option (Right to Buy) | |
| Christian Cortis | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 18,704 | 18,704 | - | - | Employee Stock Option (Right to Buy) | |
| Christian Cortis | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 126,368 | 126,368 | - | - | Common Stock | |
| Alise S. Reicin | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 33,923 | 33,923 | - | - | Employee Stock Option (Right to Buy) | |
| Alise S. Reicin | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 289,600 | 289,600 | - | - | Employee Stock Option (Right to Buy) | |
| Alise S. Reicin | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 23,380 | 23,380 | - | - | Employee Stock Option (Right to Buy) | |
| Alise S. Reicin | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 166,580 | 166,580 | - | - | Common Stock | |
| Alise S. Reicin | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 124,530 | 124,530 | - | - | Common Stock | |
| Stefan Vitorovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,760 | 11,760 | - | - | Stock Option (Right to Buy) | |
| Stefan Vitorovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 1,000,900 | 1,000,900 | - | - | Common Stock | |
| Stefan Vitorovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 27,774 | 27,774 | - | - | Common Stock | |
| Marcella Kuhlman Ruddy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 18,704 | 18,704 | - | - | Employee Stock Option (Right to Buy) | |
| Marcella Kuhlman Ruddy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 32,065 | 32,065 | - | - | Common Stock | |
| Marcella Kuhlman Ruddy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 81,700 | 81,700 | - | - | Employee Stock Option (Right to Buy) | |
| Marcella Kuhlman Ruddy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 43,946 | 43,946 | - | - | Employee Stock Option (Right to Buy) | |
| Peter McNamara | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 32,065 | 32,065 | - | - | Employee Stock Option (Right to Buy) | |
| Peter McNamara | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 77,000 | 77,000 | - | - | Employee Stock Option (Right to Buy) | |
| Peter McNamara | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 10,688 | 10,688 | - | - | Common Stock | |
| Peter McNamara | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 37,959 | 37,959 | - | - | Employee Stock Option (Right to Buy) | |
| Peter McNamara | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 18,704 | 18,704 | - | - | Employee Stock Option (Right to Buy) | |
| Marc Schwabish | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 91,214 | 91,214 | - | - | Employee Stock Option (Right to Buy) | |
| Marc Schwabish | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 61,600 | 61,600 | - | - | Employee Stock Option (Right to Buy) | |
| Marc Schwabish | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 8,016 | 8,016 | - | - | Employee Stock Option (Right to Buy) | |
| Daniel Lochner | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 118,000 | 118,000 | - | - | Employee Stock Option (Right to Buy) | |
| Erik John Ostrowski | Interim CEO, President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 40,084 | 120,249 | - | - | Restricted Stock Unit | |
| Golipour Azadeh | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 37,334 | 111,999 | - | - | Restricted Stock Unit | |
| Erik Ostrowski John | Interim CEO, President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 01 Feb 2024 | 13,099 | 29,285 (0%) | 0% | 1.2 | 15,745 | Common Stock |
| Azadeh Golipour | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 37,334 | 68,104 (0%) | 0% | 0 | Common Stock | |
| Ridha Essra | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 32,834 | 32,834 (0%) | 0% | 0 | Common Stock | |
| Avruch Steven N. | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 01 Feb 2024 | 10,812 | 22,022 (0%) | 0% | 1.2 | 12,996 | Common Stock |
| Avruch Steven N. | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 32,834 | 98,499 | - | - | Restricted Stock Unit | |
| Ridha Essra | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 32,834 | 98,499 | - | - | Restricted Stock Unit | |
| Golipour Azadeh | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 01 Feb 2024 | 12,232 | 55,872 (0%) | 0% | 1.2 | 14,698 | Common Stock |
| Ostrowski John Erik | Interim CEO, President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 40,084 | 42,384 (0%) | 0% | 0 | Common Stock | |
| Avruch Steven N. | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 32,834 | 32,834 (0%) | 0% | 0 | Common Stock | |
| Ridha Essra | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 01 Feb 2024 | 16,953 | 15,881 (0%) | 0% | 1.2 | 20,354 | Common Stock |
| Erik John Ostrowski | Interim CEO, President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2023 | 70,000 | 70,000 | - | - | Restricted Stock Unit | |
| Azadeh Golipour | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.21 per share. | 12 Jun 2023 | 111 | 30,770 (0%) | 0% | 1.2 | 134 | Common Stock |
| Azadeh Golipour | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.19 per share. | 12 Jun 2023 | 5,463 | 30,881 (0%) | 0% | 1.2 | 6,501 | Common Stock |
| Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,643 | 17,643 | - | - | Stock Option (Right to Buy) | |
| Phillip B. Donenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,643 | 17,643 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,643 | 17,643 | - | - | Stock Option (Right to Buy) | |
| Gail M. Farfel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,643 | 17,643 | - | - | Stock Option (Right to Buy) | |
| Philip J. Vickers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,643 | 17,643 | - | - | Stock Option (Right to Buy) | |
| Annalisa Mary Jenkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,643 | 17,643 | - | - | Stock Option (Right to Buy) | |
| Christopher Paige | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,643 | 17,643 | - | - | Stock Option (Right to Buy) | |
| Deanna M. Petersen | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 86,667 | 86,667 | - | - | Restricted Stock Unit | |
| Erik John Ostrowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 160,333 | 160,333 | - | - | Restricted Stock Unit | |
| Steven N. Avruch | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 131,333 | 131,333 | - | - | Restricted Stock Unit | |
| Geoff Mackay | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 300,667 | 300,667 | - | - | Restricted Stock Unit | |
| Essra Ridha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 131,333 | 131,333 | - | - | Restricted Stock Unit | |
| Azadeh Golipour | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 149,333 | 149,333 | - | - | Restricted Stock Unit | |
| Geoff Mackay | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Dec 2022 | 45,999 | 0 | - | - | Stock Option (Right to Buy) | |
| Geoff Mackay | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2022 | 245,123 | 142,013 (0%) | 0% | 0 | Common Stock | |
| Geoff Mackay | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2022 | 245,123 | 445,123 (1%) | 0% | 0 | Common Stock | |
| Geoff Mackay | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.91 per share. | 28 Dec 2022 | 45,999 | 188,012 (0%) | 0% | 0.9 | 41,859 | Common Stock |
| Geoff Mackay | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.41 per share. | 23 Dec 2022 | 142,013 | 387,136 (1%) | 0% | 0.4 | 58,680 | Common Stock |
| Geoff Mackay | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2022 | 142,013 | 0 | - | - | Stock Option (Right to Buy) | |
| Deanna M. Petersen | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2022 | 111,500 | 111,500 | - | - | Stock Option (Right to Buy) | |
| Erik John Ostrowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2022 | 221,000 | 221,000 | - | - | Stock Option (Right to Buy) | |
| Steven N. Avruch | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2022 | 169,500 | 169,500 | - | - | Stock Option (Right to Buy) | |
| Geoff Mackay | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2022 | 388,000 | 388,000 | - | - | Stock Option (Right to Buy) | |
| Essra Ridha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2022 | 183,000 | 183,000 | - | - | Stock Option (Right to Buy) | |
| Azadeh Golipour | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2022 | 165,000 | 165,000 | - | - | Stock Option (Right to Buy) | |
| Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Phillip B. Donenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Phillip B. Donenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Gail M. Farfel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Gail M. Farfel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Philip J. Vickers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Philip J. Vickers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Annalisa Mary Jenkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Annalisa Mary Jenkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Christopher Paige | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Christopher Paige | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Deanna M. Petersen | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Deanna M. Petersen | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Erik John Ostrowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| Erik John Ostrowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| Steven N. Avruch | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Steven N. Avruch | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Geoff Mackay | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 328,500 | 328,500 | - | - | Stock Option (Right to Buy) | |
| Geoff Mackay | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 405,000 | 405,000 | - | - | Stock Option (Right to Buy) | |
| Essra Ridha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Essra Ridha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Essra Ridha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Philip J. Vickers | Director | Purchase of securities on an exchange or from another person at price $ 8.35 per share. | 07 Jul 2021 | 4,800 | 4,800 (0%) | 0% | 8.4 | 40,080 | Common Stock |
| Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 17,438 | 17,438 | - | - | Stock Option (Right to Buy) | |
| Phillip B. Donenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 17,438 | 17,438 | - | - | Stock Option (Right to Buy) | |
| Deanna M. Petersen | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 17,438 | 17,438 | - | - | Stock Option (Right to Buy) | |
| Gail M. Farfel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 17,438 | 17,438 | - | - | Stock Option (Right to Buy) | |
| Philip J. Vickers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 17,438 | 17,438 | - | - | Stock Option (Right to Buy) | |
| Erik Ostrowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Annalisa Mary Jenkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 17,438 | 17,438 | - | - | Stock Option (Right to Buy) | |
| Steven N. Avruch | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Geoff Mackay | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Paige | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 17,438 | 17,438 | - | - | Stock Option (Right to Buy) | |
| Diana M. Escolar | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Mason | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Phillip B. Donenberg | Director | Purchase of securities on an exchange or from another person at price $ 11.71 per share. | 17 Feb 2021 | 2,000 | 2,000 (0%) | 0% | 11.7 | 23,420 | Common Stock |
| Deanna M. Petersen | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 86,600 | 86,600 | - | - | Stock Option (Right to Buy) | |
| Erik Ostrowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 119,100 | 119,100 | - | - | Stock Option (Right to Buy) | |
| Steven N. Avruch | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 98,200 | 98,200 | - | - | Stock Option (Right to Buy) | |
| Geoff Mackay | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 343,850 | 343,850 | - | - | Stock Option (Right to Buy) | |
| Diana M. Escolar | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Geoff Mackay | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.41 per share. | 24 Dec 2020 | 100,000 | 245,123 (0%) | 0% | 0.4 | 41,320 | Common Stock |
| Geoff Mackay | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Dec 2020 | 100,000 | 142,013 | - | - | Stock Option (Right to Buy) | |
| Gail M. Farfel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2020 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Phillip B. Donenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Philip J. Vickers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Annalisa Mary Jenkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Paige | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Deanna M. Petersen | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2020 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Erik Ostrowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2020 | 100,900 | 100,900 | - | - | Stock Option (Right to Buy) | |
| Steven N. Avruch | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2020 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Geoff Mackay | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2020 | 292,300 | 292,300 | - | - | Stock Option (Right to Buy) | |
| Birgitte Volck | President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2020 | 76,000 | 76,000 | - | - | Stock Option (Right to Buy) | |
| Geoff Mackay | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 29.07 per share. | 12 Feb 2020 | 1,400 | 345,123 (1%) | 0% | 29.1 | 40,692 | Common Stock |
| Geoff Mackay | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 27.36 per share. | 11 Feb 2020 | 44,596 | 364,927 (1%) | 0% | 27.4 | 1,219,982 | Common Stock |
| Geoff Mackay | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 28.10 per share. | 11 Feb 2020 | 18,404 | 346,523 (1%) | 0% | 28.1 | 517,099 | Common Stock |
| Christopher Paige | Director | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 11 Feb 2020 | 15,000 | 252,512 (0%) | 0% | 28 | 420,000 | Common Stock |
| Christopher Paige | Director | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 28 Jan 2020 | 10,000 | 267,512 (0%) | 0% | 23 | 230,000 | Common Stock |
| Geoff Mackay | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 200,000 | 145,123 (0%) | 0% | 0 | Common Stock | |
| Bruce Booth | Director | Purchase of securities on an exchange or from another person at price $ 18.50 per share. | 19 Jul 2019 | 810,811 | 5,567,289 (17%) | 2% | 18.5 | 15,000,004 | Common Stock |
| Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 9,675 | 9,675 | - | - | Stock Option (Right to Buy) | |
| Phillip B. Donenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 9,675 | 9,675 | - | - | Stock Option (Right to Buy | |
| Bruce Booth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 9,675 | 9,675 | - | - | Stock Option (Right to Buy) | |
| Philip J. Vickers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 9,675 | 9,675 | - | - | Stock Option (Right to Buy) | |
| Annalisa Mary Jenkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 9,675 | 9,675 | - | - | Stock Option (Right to Buy) | |
| Christopher Paige | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 9,675 | 9,675 | - | - | Stock Option (Right to Buy) | |
| Geoff Mackay | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 27.26 per share. | 05 Apr 2019 | 13,302 | 410,221 (1%) | 0% | 27.3 | 362,618 | Common Stock |
| Geoff Mackay | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 27.07 per share. | 05 Apr 2019 | 698 | 409,523 (1%) | 0% | 27.1 | 18,893 | Common Stock |
| Christopher Paige | Director | Sale of securities on an exchange or to another person at price $ 26.92 per share. | 05 Apr 2019 | 100 | 277,512 (0%) | 0% | 26.9 | 2,692 | Common Stock |
| Christopher Paige | Director | Sale of securities on an exchange or to another person at price $ 25.59 per share. | 05 Apr 2019 | 6,633 | 280,879 (0%) | 0% | 25.6 | 169,759 | Common Stock |
| Christopher Paige | Director | Sale of securities on an exchange or to another person at price $ 26.21 per share. | 05 Apr 2019 | 867 | 280,012 (0%) | 0% | 26.2 | 22,724 | Common Stock |
| Christopher Paige | Director | Sale of securities on an exchange or to another person at price $ 25.84 per share. | 05 Apr 2019 | 2,400 | 277,612 (0%) | 0% | 25.8 | 62,021 | Common Stock |
| Geoff Mackay | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2019 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Philip J. Vickers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2019 | 18,743 | 18,743 | - | - | Stock Option (Right to Buy) | |
| Erik John Ostrowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 186,000 | 186,000 | - | - | Stock Option (Right to Buy) | |
| Erik John Ostrowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 2,300 | 2,300 (0%) | 0% | 0 | Common Stock | |
| Steven N. Avruch | VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 88,636 | 88,636 | - | - | Stock Option (Right to Buy) | |
| Birgitte Volck | President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2018 | 293,000 | 293,000 | - | - | Stock Option (Right to Buy) | |
| Katina Dorton | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2018 | 10,000 | 148,318 | - | - | Stock Option (Right to Buy) | |
| Katina Dorton | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.91 per share. | 08 Oct 2018 | 10,000 | 10,000 (0%) | 0% | 0.9 | 9,100 | Common Stock |
| Nerissa Kreher | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.91 per share. | 08 Oct 2018 | 2,942 | 2,942 (0%) | 0% | 0.9 | 2,677 | Common Stock |
| Nerissa Kreher | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2018 | 2,942 | 24,629 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | None | 25 Jun 2018 | 3,333,333 | 0 | - | - | Series Seed Preferred Stock | ||
| Bruce Booth | None | 25 Jun 2018 | 905,188 | 4,756,478 (20%) | 3% | 0 | Common Stock | ||
| Bruce Booth | None | 25 Jun 2018 | 3,044,579 | 3,851,290 (16%) | 13% | 0 | Common Stock | ||
| Bruce Booth | None | 25 Jun 2018 | 806,711 | 806,711 (3%) | 3% | 0 | Common Stock | ||
| Bruce Booth | None | 25 Jun 2018 | 3,740,239 | 0 | - | - | Series B Preferred Stock | ||
| Bruce Booth | None | 25 Jun 2018 | 12,580,199 | 0 | - | - | Series A Preferred Stock | ||
| Scott Requadt | None | 25 Jun 2018 | 678,891 | 2,962,325 (12%) | 2% | 0 | Common Stock | ||
| Scott Requadt | None | 25 Jun 2018 | 2,283,434 | 2,283,434 (9%) | 9% | 0 | Common Stock | ||
| Scott Requadt | None | 25 Jun 2018 | 2,805,179 | 0 | - | - | Series B Preferred Stock | ||
| Scott Requadt | None | 25 Jun 2018 | 9,435,150 | 0 | - | - | Series A Preferred Stock | ||
| Phillip B. Donenberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2018 | 18,743 | 18,743 | - | - | Stock Option (Right to Buy) |